APA (7th ed.) Citation

Y, C., S, D., CS, C., & L, C. (2024). Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: Mechanistic insights, clinical efficacy, and future perspectives. Journal of hematology & oncology, 17(1), 130. https://doi.org/10.1186/s13045-024-01647-1

Chicago Style (17th ed.) Citation

Y, Chen, Dai S, Cheng CS, and Chen L. "Lenvatinib and Immune-checkpoint Inhibitors in Hepatocellular Carcinoma: Mechanistic Insights, Clinical Efficacy, and Future Perspectives." Journal of Hematology & Oncology 17, no. 1 (2024): 130. https://doi.org/10.1186/s13045-024-01647-1.

MLA (9th ed.) Citation

Y, Chen, et al. "Lenvatinib and Immune-checkpoint Inhibitors in Hepatocellular Carcinoma: Mechanistic Insights, Clinical Efficacy, and Future Perspectives." Journal of Hematology & Oncology, vol. 17, no. 1, 2024, p. 130, https://doi.org/10.1186/s13045-024-01647-1.